Latest Breaking News On - Drug registration regulation - Page 1 : comparemela.com

Zai Lab Announces That Repotrectinib Granted Priority Review by China's NMPA

SHANGHAI, China and CAMBRIDGE, Mass., May 18, 2023 Zai Lab Limited today announced that the Center for Drug Evaluation of China’s National Medical Products Administration has granted. | May 18, 2023

Form 424B3 NewAmsterdam Pharma Co

Spotlight on Greater China: out-licensing to Chinese counterparties | Hogan Lovells

As part of a new Asia-Pacific (APAC) Life Sciences and Health Care webinar program designed both for companies with commercial interests in APAC and for companies based in the region,.

Amgen Announces Breakthrough Therapy Designation Granted For Sotorasib In China

Amgen Announces Breakthrough Therapy Designation Granted For Sotorasib In China Sotorasib is for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients With KRAS G12C Mutation News provided by Share this article Share this article THOUSAND OAKS, Calif., Jan. 29, 2021 /PRNewswire/ Amgen (NASDAQ: AMGN) today announced that its investigational KRAS G12C inhibitor sotorasib was granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The designation is for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. This is the first BTD submission for Amgen in China, as well as the first under Amgen s strategic collaboration with BeiGene. 

APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.